Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies

Joseph M Rocco; Lindsey B Rosen; Gloria H Hong; Jennifer Treat; Samantha Kreuzburg; Steven M Holland; Christa S Zerbe

doi:10.1016/j.jtauto.2021.100102

Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies

J Transl Autoimmun. 2021 May 4:4:100102. doi: 10.1016/j.jtauto.2021.100102. eCollection 2021.

Authors

Joseph M Rocco¹, Lindsey B Rosen¹, Gloria H Hong², Jennifer Treat¹, Samantha Kreuzburg¹, Steven M Holland¹, Christa S Zerbe¹

Affiliations

¹ National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
² Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Abstract

Interferon-γ autoantibodies increase the risk of disseminated nontuberculous mycobacterial infections. Addition of rituximab to antibiotics accelerates and improves outcomes, but refractory infections can occur due to persistent production of autoantibodies. We combined bortezomib with rituximab to reduce autoantibodies leading to clinical and radiographic improvement in infection.

Keywords: Autoantibodies; Bortezomib; Interferon gamma; Nontuberculous mycobacteria; Rituximab.

Publication types

Case Reports